First procedure in Netherlands with NaoTrac surgical navigation robot is performed at Erasmus MC Rotterdam
HSINCHU, July 17, 2024 /PRNewswire/ -- Brain Navi announces the completion of its first case in Netherlands, which was successfully and safely performed at Erasmus MC in Rotterdam, Netherlands. Brain biopsy helps doctors decide the best treatment for the patient after taking a tissue sample from the brain, usually under general anesthetic....
New COSMOS research reveals Centrum Silver supports cognitive health in healthy older adults
The simple act of taking Centrum Silver multivitamin supplements daily can support cognition among those aged 60 years and above Experts emphasise the relevance of cognitive decline as a critical age-related health issue in Singapore given its aging population, and spotlight the importance of multivitamin supplements in supporting cognitive health Cognitive...
111, Inc. to Participate in Fireside Chat with Water Tower Research on July 18, 2024
SHANGHAIJuly 17, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst of Water Tower Research ("WTR") on...
GCCL Completes Proactive Development of Biosimilar Clinical Trial Analysis Methods, Providing Customized Analysis Services through Enhanced R&D Capabilities
Newly established R&D division this year is expected to provide full-scale in-house R&D in addition to clinical sample analysis Including blockbuster drugs such as 'Keytruda' and 'Yervoy', GCCL offers tailored clinical trial analysis services for biosimilar development YONGIN, South Korea, July 17, 2024 /PRNewswire/ -- GCCL, a clinical trial sample analysis institution, has proactively developed pharmacokinetic (PK) analysis...
CordenPharma Invests €900m in Transformational Peptide Platform Expansion in the USA & Europe
CordenPharma is making a record investment of ~€900m over the next 3 years in expanding its peptide platform, both at its Colorado, US site and in Europe. The expansions, covering both existing facilities and new constructions, will meet the pharmaceutical industry's most stringent quality and technical standards for short and long peptide manufacturing, including BLA requirements. The Colorado,...
Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors
Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' radiopharmaceutical compound into an innovative anti-cancer treatment for worldwide markets HEIDELBERG, Germany and SEOUL, South Korea, July 17, 2024 /PRNewswire/ -- Full-Life Technologies ("Full-Life"), a fully integrated global radiotherapeutics company, announced today that it has entered into a license agreement with SK Biopharmaceuticals, a global biotech...
Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery, Upcoming Webinar Hosted by HitGen and Xtalks
CHENGDU, China, July 16, 2024 /PRNewswire/ -- "Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery" webinar will be jointly hosted by HitGen Inc. and Xtalks on Wednesday July 17, 2024, at 2pm EDT (11am PDT). Alex Shaginian, PhD, Vice President of Business Development and Chemical Sciences, HitGen, David Israel, PhD,...
ShiraTronics Unveils Data on their Neurostimulation System for Chronic Migraine
MIAMI BEACH, Fla., July 17, 2024 /PRNewswire/ -- ShiraTronics, a trailblazing clinical-stage neurostimulation company, proudly presented findings from its Australian Pilot Study, RELIEV-CM, at the American Society of Pain and Neuroscience (ASPN) Pain Conference. This pioneering study showcases the world's first fully implantable neurostimulation system specifically engineered for chronic migraine. ...
FDA Grants Orphan Drug Designation to 7MW3711
SHANGHAI, July 16, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel B7-H3-targeting ADC (R&D code: 7MW3711) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA), for the treatment of small cell lung cancer. The FDA grants Orphan Drug Designation to treatments for rare diseases in...
Athletes’ health – effects of environmental pollutants and nutrition on epithelial barrier function and healthy microbes in the body
Novel concepts highlight a holistic approach to overall health and physical performance of athletes (professional sporters and physically active persons), linked with their nutrition and exposure to pollution and toxic substances affecting the integrity of their barriers of skin and mucosal body surfaces and healthy microbiome. DAVOS, Switzerland, July 16, 2024 /PRNewswire/ -- The health of athletes and physically...
